Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits Reuters Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type BioCentury Early data from Novo's CagriSema competitive with Lilly's Mounjaro